{"id":65320,"date":"2026-05-14T19:33:13","date_gmt":"2026-05-14T11:33:13","guid":{"rendered":"https:\/\/flcube.com\/?p=65320"},"modified":"2026-05-14T19:33:14","modified_gmt":"2026-05-14T11:33:14","slug":"shanghai-implements-fixed-amount-reimbursement-model-for-11th-nvbp-drugs-patients-bear-excess-costs-above-winning-prices","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65320","title":{"rendered":"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices"},"content":{"rendered":"\n<p>The <strong>Shanghai Municipal Healthcare Security Bureau<\/strong> issued the <strong>&#8220;Notice on Optimizing Payment Coordination for the 11th National Volume-Based Procurement (NVBP) Drugs&#8221;<\/strong>, effective <strong>May 1, 2026<\/strong>. The policy implements a <strong>&#8220;fixed-amount reimbursement&#8221; model<\/strong> that caps insurance coverage at NVBP winning prices, with patients responsible for any excess costs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-policy-framework-amp-reimbursement-structure\">Policy Framework &amp; Reimbursement Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Scenario<\/th><th>Reimbursement Standard<\/th><th>Patient Cost Sharing<\/th><\/tr><\/thead><tbody><tr><td><strong>Drugs \u2264 Reimbursement Standard<\/strong><\/td><td>Actual selling price<\/td><td>Shared between patient and insurance fund per policy<\/td><\/tr><tr><td><strong>Drugs &gt; Reimbursement Standard<\/strong><\/td><td>Capped at NVBP winning price<\/td><td>Up to standard: shared per policy; Excess: 100% out-of-pocket (OOP)<\/td><\/tr><tr><td><strong>Five Indication-Based Drugs<\/strong><\/td><td>Special higher OOP ratios<\/td><td>Essential\/Class A: +20% OOP; Others: +30% OOP<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-policy-components\">Key Policy Components<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-fixed-amount-reimbursement-model\">Fixed-Amount Reimbursement Model<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Generic Name Basis:<\/strong> Reimbursement standards determined by generic name (including formulation)<\/li>\n\n\n\n<li><strong>NVBP Price Cap:<\/strong> Winning NVBP prices serve as reimbursement ceiling<\/li>\n\n\n\n<li><strong>Patient Financial Responsibility:<\/strong> Excess costs above winning prices borne entirely by patients<\/li>\n\n\n\n<li><strong>OOP Classification:<\/strong> Excess amounts counted toward patient&#8217;s out-of-pocket category<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-five-indication-based-volume-procurement-drugs\">Five Indication-Based Volume Procurement Drugs<\/h3>\n\n\n\n<p>The following drugs receive special treatment with <strong>enhanced patient cost-sharing<\/strong>:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Olaparib<\/strong> oral solid dosage form<\/li>\n\n\n\n<li><strong>Dapagliflozin<\/strong> oral solid dosage form<\/li>\n\n\n\n<li><strong>Avatrombopag maleate<\/strong> oral solid dosage form<\/li>\n\n\n\n<li><strong>Eltrombopag olamine<\/strong> oral solid dosage form<\/li>\n\n\n\n<li><strong>Nintedanib esylate<\/strong> oral solid dosage form<\/li>\n<\/ol>\n\n\n\n<p>For these drugs, non-winning &#8220;high-priced&#8221; versions trigger <strong>20-30% higher OOP ratios<\/strong> depending on drug classification.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-institutional-incentives-amp-procurement-guidelines\">Institutional Incentives &amp; Procurement Guidelines<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Price Adjustment Encouragement:<\/strong> Non-winning manufacturers urged to align prices with similar products<\/li>\n\n\n\n<li><strong>Procurement Priority:<\/strong> Medical institutions encouraged to prioritize drugs priced at or below reimbursement standard<\/li>\n\n\n\n<li><strong>DRG\/DIP Savings Retention:<\/strong> Rational drug use savings retained as institutional incentives upon settlement<\/li>\n\n\n\n<li><strong>Primary Care Flexibility:<\/strong> Primary facilities supported in stocking non-winning drugs based on clinical needs<\/li>\n\n\n\n<li><strong>No Ratio Requirements:<\/strong> No procurement ratio mandates for non-winning drugs in primary care for NVBP-targeted varieties<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-enhanced-primary-care-access\">Enhanced Primary Care Access<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class B Drug Reimbursement:<\/strong> Class B drugs reimbursed using Class A rules in primary care settings<\/li>\n\n\n\n<li><strong>Full Coverage Below Standard:<\/strong> Costs under reimbursement standard fully covered with no patient OOP<\/li>\n\n\n\n<li><strong>Medication Access Assurance:<\/strong> Policy ensures continued patient access to necessary medications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-stakeholder-implications\">Market Impact &amp; Stakeholder Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharmaceutical-manufacturers\">Pharmaceutical Manufacturers<\/h3>\n\n\n\n<p><strong>Winning Companies:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Guaranteed market access with full insurance coverage<\/li>\n\n\n\n<li>Competitive advantage through price-based reimbursement structure<\/li>\n<\/ul>\n\n\n\n<p><strong>Non-Winning Companies:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Significant pricing pressure to match or approach NVBP winning prices<\/li>\n\n\n\n<li>Risk of market share erosion unless price adjustments are implemented<\/li>\n\n\n\n<li>Potential need to restructure commercial strategies for Shanghai market<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-healthcare-providers\">Healthcare Providers<\/h3>\n\n\n\n<p><strong>Hospitals &amp; Clinics:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Financial incentives to select cost-effective NVBP drugs<\/li>\n\n\n\n<li>DRG\/DIP savings retention creates direct economic benefit from rational prescribing<\/li>\n\n\n\n<li>Reduced administrative burden through simplified reimbursement calculations<\/li>\n<\/ul>\n\n\n\n<p><strong>Primary Care Facilities:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enhanced flexibility in drug selection while maintaining patient affordability<\/li>\n\n\n\n<li>Improved ability to meet diverse clinical needs without compromising access<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-patients-amp-payers\">Patients &amp; Payers<\/h3>\n\n\n\n<p><strong>Patient Impact:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Clear cost transparency with predictable OOP expenses<\/li>\n\n\n\n<li>Potential financial burden for choosing non-NVBP drugs without clinical justification<\/li>\n\n\n\n<li>Maintained access to necessary medications through primary care provisions<\/li>\n<\/ul>\n\n\n\n<p><strong>Insurance Fund Benefits:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Predictable expenditure control through fixed reimbursement ceilings<\/li>\n\n\n\n<li>Reduced overall drug spending while maintaining therapeutic outcomes<\/li>\n\n\n\n<li>Alignment with national cost-containment objectives<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-for-china-s-healthcare-reform\">Strategic Significance for China&#8217;s Healthcare Reform<\/h2>\n\n\n\n<p>This Shanghai policy represents a critical evolution in China&#8217;s volume-based procurement implementation, moving beyond simple price competition to <strong>comprehensive payment coordination<\/strong>. The fixed-amount reimbursement model creates powerful market signals that reinforce NVBP objectives while maintaining patient access through carefully designed safety nets.<\/p>\n\n\n\n<p>The policy demonstrates Shanghai&#8217;s role as a <strong>pioneer in healthcare payment reform<\/strong>, potentially serving as a template for other provinces implementing similar NVBP coordination measures.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding policy implementation, market impacts, and stakeholder responses. Actual outcomes may vary based on execution effectiveness, stakeholder adaptation, competitive dynamics, and evolving regulatory frameworks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Shanghai Municipal Healthcare Security Bureau issued the &#8220;Notice on Optimizing Payment Coordination for the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65321,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[],"class_list":["post-65320","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Shanghai Municipal Healthcare Security Bureau issued the &quot;Notice on Optimizing Payment Coordination for the 11th National Volume-Based Procurement (NVBP) Drugs&quot;, effective May 1, 2026. The policy implements a &quot;fixed-amount reimbursement&quot; model that caps insurance coverage at NVBP winning prices, with patients responsible for any excess costs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65320\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices\" \/>\n<meta property=\"og:description\" content=\"The Shanghai Municipal Healthcare Security Bureau issued the &quot;Notice on Optimizing Payment Coordination for the 11th National Volume-Based Procurement (NVBP) Drugs&quot;, effective May 1, 2026. The policy implements a &quot;fixed-amount reimbursement&quot; model that caps insurance coverage at NVBP winning prices, with patients responsible for any excess costs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65320\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T11:33:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T11:33:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1401-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices\",\"datePublished\":\"2026-05-14T11:33:13+00:00\",\"dateModified\":\"2026-05-14T11:33:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320\"},\"wordCount\":615,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1401-1.webp\",\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65320#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65320\",\"name\":\"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1401-1.webp\",\"datePublished\":\"2026-05-14T11:33:13+00:00\",\"dateModified\":\"2026-05-14T11:33:14+00:00\",\"description\":\"The Shanghai Municipal Healthcare Security Bureau issued the \\\"Notice on Optimizing Payment Coordination for the 11th National Volume-Based Procurement (NVBP) Drugs\\\", effective May 1, 2026. The policy implements a \\\"fixed-amount reimbursement\\\" model that caps insurance coverage at NVBP winning prices, with patients responsible for any excess costs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65320\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1401-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1401-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65320#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices - Insight, China&#039;s Pharmaceutical Industry","description":"The Shanghai Municipal Healthcare Security Bureau issued the \"Notice on Optimizing Payment Coordination for the 11th National Volume-Based Procurement (NVBP) Drugs\", effective May 1, 2026. The policy implements a \"fixed-amount reimbursement\" model that caps insurance coverage at NVBP winning prices, with patients responsible for any excess costs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65320","og_locale":"en_US","og_type":"article","og_title":"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices","og_description":"The Shanghai Municipal Healthcare Security Bureau issued the \"Notice on Optimizing Payment Coordination for the 11th National Volume-Based Procurement (NVBP) Drugs\", effective May 1, 2026. The policy implements a \"fixed-amount reimbursement\" model that caps insurance coverage at NVBP winning prices, with patients responsible for any excess costs.","og_url":"https:\/\/flcube.com\/?p=65320","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T11:33:13+00:00","article_modified_time":"2026-05-14T11:33:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1401-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65320#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65320"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices","datePublished":"2026-05-14T11:33:13+00:00","dateModified":"2026-05-14T11:33:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65320"},"wordCount":615,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65320#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1401-1.webp","articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65320#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65320","url":"https:\/\/flcube.com\/?p=65320","name":"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65320#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65320#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1401-1.webp","datePublished":"2026-05-14T11:33:13+00:00","dateModified":"2026-05-14T11:33:14+00:00","description":"The Shanghai Municipal Healthcare Security Bureau issued the \"Notice on Optimizing Payment Coordination for the 11th National Volume-Based Procurement (NVBP) Drugs\", effective May 1, 2026. The policy implements a \"fixed-amount reimbursement\" model that caps insurance coverage at NVBP winning prices, with patients responsible for any excess costs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65320#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65320"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65320#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1401-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1401-1.webp","width":1080,"height":608,"caption":"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65320#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs \u2013 Patients Bear Excess Costs Above Winning Prices"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1401-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65320"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65320\/revisions"}],"predecessor-version":[{"id":65322,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65320\/revisions\/65322"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65321"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}